Latest preprint reviews

  1. Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a g BRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1

    This article has 32 authors:
    1. Ezra Y. Rosen
    2. Marie-Claude Mathieu
    3. Gino B. Ferraro
    4. Philippe Mochirian
    5. Claude Godbout
    6. Hugo Poirier
    7. Sara Fournier
    8. Danielle Henry
    9. Hyeyeon Kim
    10. Robert Papp
    11. Shou Yun Yin
    12. Marie-Eve Leclaire
    13. Robert Houle
    14. Parham Nejad
    15. Joseph D. Schonhoft
    16. Karl E. Zahn
    17. W. Cameron Black
    18. Michel Gallant
    19. Insil Kim
    20. Danielle Ulanet
    21. Paul Basciano
    22. Artur Veloso
    23. Victoria Rimkunas
    24. Timothy A. Yap
    25. Robin Guo
    26. Nicholas Mai
    27. Maria Koehler
    28. Michael Zinda
    29. Anne Roulston
    30. Michal Zimmermann
    31. Stephen J. Morris
    32. Agnel Sfeir
    This article has been curated by 1 group:
    • Curated by eLife

      eLife Assessment

      Loss of POLQ function is synthetically lethal with BRCA1 or BRCA2 deficiency, as is pharmacological inhibition of its motor (ATPase) or polymerase activity. This important manuscript validates an inhibitor of the DNA polymerase theta (POLθ) motor domain in biochemical and cell-based assays and provides evidence of its efficacy against homologous recombination-deficient tumors in preclinical and clinical settings, particularly in combination with PARP inhibitors. The experiments are rigorous, the evidence is convincing, and the results are appropriately interpreted. This work will be of considerable interest to the ovarian cancer research community.

    Reviewed by eLife

    This article has 5 evaluationsAppears in 1 listLatest version Latest activity
Page 1 of 873 Older